Permanens Capital’s Ovid Therapeutics OVID Stock Holding History

Permanens Capital’s Portfolio OVID Stock Details OVID Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-300	Closed	-$1K	–	85
2021 Q2	$1K	Hold	300	–	–	﹤0.01%	109
2021 Q1	$1K	Hold	300	–	–	﹤0.01%	124
2020 Q4	$1K	Hold	300	–	–	﹤0.01%	123
2020 Q3	$2K	Hold	300	–	–	﹤0.01%	110
2020 Q2	$2K	Buy	+300	New	+$1.4K	﹤0.01%	106

Other funds holding OVID

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SCM

Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return

Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Globeflex Capital San Diego, California $783M AUM 81.58% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

PIM

Platinum Investment Management Sydney Australia 2000, Australia $407M AUM 87.11% 1-Year Est. Return

Permanens Capital's OVID Position: Q3 2021 in Review

Permanens Capital sold out of Ovid Therapeutics (OVID) in Q3 2021, closing a stake of 300 shares — an estimated $1K sold.

Permanens Capital first reported a position in OVID in Q2 2020 and held it in 5 quarters. The position peaked at $2K in Q3 2020. 72 funds tracked by Wall St. Rank hold OVID as of Q3 2021.

Permanens Capital reported no remaining Ovid Therapeutics position as of Q3 2021 after selling out during the quarter.
Permanens Capital sold 300 Ovid Therapeutics shares in Q3 2021, an estimated $1K.
Permanens Capital first reported a position in Ovid Therapeutics in Q2 2020 and held it in 5 quarters.
Permanens Capital's Ovid Therapeutics position peaked at $2K in Q3 2020.
72 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q3 2021.

Based on Permanens Capital's 13F filing for Q3 2021, filed 12 Nov 2021.